(Total Views: 388)
Posted On: 02/26/2021 12:07:01 PM
Post# of 153905
Henry,
I agree that an EUA is coming.
IMO the changed FDA analysis extending to 42 and 60 analysis is much more about aviptadil.
It appears, that though their trial failed at 28 days, that they will demonstrate efficacy at 42 or 60 days.
While the longer assessment period will not hurt the evaluation of leronlimab, I have no doubt that leronlimab demonstrated efficacy over a much shorter interval.
I agree that an EUA is coming.
IMO the changed FDA analysis extending to 42 and 60 analysis is much more about aviptadil.
It appears, that though their trial failed at 28 days, that they will demonstrate efficacy at 42 or 60 days.
While the longer assessment period will not hurt the evaluation of leronlimab, I have no doubt that leronlimab demonstrated efficacy over a much shorter interval.
(3)
(0)
